Titan Medical (NASDAQ:TMDI) Stock Rating Lowered by Zacks Investment Research

Titan Medical (NASDAQ:TMDI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports.

According to Zacks, “Titan Medical Inc. is focused on the design and development of a robotic surgical system for application in minimally invasive surgery. The Company’s SPORT Surgical System includes a surgeon-controlled robotic platform which incorporates a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures through a single incision. The surgical system also includes a surgeon workstation which provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and viewing the inside of a patient’s body in 3D during MIS procedures. Titan Medical Inc. is based in ON, Canada. “

Several other equities research analysts have also recently issued reports on the stock. Oppenheimer started coverage on shares of Titan Medical in a research note on Tuesday, April 6th. They set an “outperform” rating and a $4.00 target price on the stock. Bloom Burton reaffirmed a “buy” rating on shares of Titan Medical in a research note on Monday, April 19th.

Shares of TMDI opened at $1.83 on Wednesday. Titan Medical has a 52-week low of $0.57 and a 52-week high of $3.47. The business’s fifty day simple moving average is $1.73. The firm has a market cap of $200.44 million, a PE ratio of -4.16 and a beta of 3.17.

Several hedge funds have recently made changes to their positions in the company. Cito Capital Group LLC acquired a new position in shares of Titan Medical during the 1st quarter valued at about $270,000. Captrust Financial Advisors boosted its position in shares of Titan Medical by 708.2% during the 1st quarter. Captrust Financial Advisors now owns 56,976 shares of the company’s stock valued at $97,000 after acquiring an additional 49,926 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Titan Medical by 85.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,089,983 shares of the company’s stock valued at $1,850,000 after acquiring an additional 500,783 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Titan Medical by 22.9% during the 1st quarter. Geode Capital Management LLC now owns 33,451 shares of the company’s stock valued at $56,000 after acquiring an additional 6,235 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Titan Medical by 14.8% during the 1st quarter. JPMorgan Chase & Co. now owns 77,500 shares of the company’s stock valued at $132,000 after acquiring an additional 10,000 shares during the last quarter. 2.56% of the stock is currently owned by hedge funds and other institutional investors.

About Titan Medical

Titan Medical Inc, a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the Enos robotic single-access surgical system (Enos system), a single-port robotic surgical system that includes a surgeon-controlled patient cart that includes a 3D high definition vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during MIS procedures.

Read More: What are convertible shares? 

Get a free copy of the Zacks research report on Titan Medical (TMDI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Titan Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Medical and related companies with MarketBeat.com's FREE daily email newsletter.